This was confirmed by Harley and co-workers, who identified CD44 as a key driver of glioma malignancy with cells encapsulated in gelatin and PEG-based hydrogels grafted with a HA hydrogel network (Pedron et al., 2013). The gene discussed is CD44; the disease is central nervous system cancer.